A Roche study into using a combination of tiragolumab and tecentriq to treat a form of lung cancer in a phase III trial did ...

With targeted treatment and a strong support group, she now lives a full life and serves the community that had her back.

In 2022, the Swiss pharma giant said SKYSCRAPER-01 failed to reach the co-primary goal of progression-free survival. The ...

A cancer treatment from Roche failed to improve survival in a major lung cancer study, a result that will stoke doubts about ...

引言癌症是当今世界上最具挑战性的健康问题之一，尤其是肺癌，作为致死率最高的癌症类型，每年夺走数百万人的生命。随着研究人员对癌症的深入研究，人们逐渐认识到，癌症不仅仅是恶性细胞的过度增殖，更是一种与“宿主”复杂相互作用的生态系统。肿瘤微环境（Tumor ...

Roche’s Skyscraper-01 has fallen down. The phase 3 trial found adding the TIGIT candidate tiragolumab to a checkpoint ...

Tiragolumab missed the chance to prove a survival benefit in SKYSCRAPER-01 adding to previous trial failures for the ...

Panelist discusses how the future treatment landscape for EGFR-mutant advanced non–small cell lung cancer is evolving to address current unmet needs and offers clinical pearls to community oncologists ...

Susan Wojcicki, a non-smoker and CEO of YouTube, was diagnosed with non-small cell lung cancer in 2022 at the age of 56. She ...

When Ed O. went to the ER for shortness of breath and trembling, he never imagined he’d receive a diagnosis of unresectable ...

Genentech announced that the Phase III SKYSCRAPER-01 study, which evaluated tiragolumab combined with Tecentriq (atezolizumab) versus ...